🔥🐔 BizChicken 🐔🔥
Companies Similar to Generation Bio Co.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
Precigen, Inc.
gene and cellular therapies
Precigen, Inc. is focused on discovering and developing advanced gene and cellular therapies, disease-modifying therapeutics, and genetic engineering technologies for regenerative medicine and other applications.
About | Contact | Careers | Careers | Careers | About | About | Benefits | Careers | About | About | About | Careers | Careers | About
Symbol: PGEN
Recent Price: $0.93
Industry: Biotechnology
CEO: Dr. Helen Sabzevari MPH, Ph.D.
Sector: Healthcare
Employees: 202
Address: 20374 Seneca Meadows Parkway, Germantown, MD 20876
Phone: 301 556 9900
Last updated: 2024-12-31
Sangamo Therapeutics, Inc.
ZFP Technology Platform
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company that develops genomic medicines using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation with a focus on transforming patients' lives.
Contact | About | About | Leadership | Leadership | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | DEI | Benefits | About | About | About | About | About | About | About | News | Events | Vision/Values | DEI | Benefits | Careers | Careers | About | About
Symbol: SGMO
Recent Price: $2.34
Industry: Biotechnology
CEO: Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Sector: Healthcare
Employees: 405
Address: 501 Canal Blvd, Brisbane California, CALIFORNIA 94005
Phone: 510 970 6000
Leadership
- Sandy Macrae, M.B., Ch.B., Ph.D.,
- Gregory Davis, Ph.D., Head of Research and Technology
- Nathalie Dubois-Stringfellow, Ph.D., Chief Development Officer
- Prathyusha Duraibabu, Chief Financial Officer
- Phillip Ramsey, Head of Technical Operations
- Stephanie J. Seiler, CLP, Head of Business Development & Alliance Management
- Louise Wilkie, Global Corporate Communications and Investor Relations
- Scott Willoughby, General Counsel and Corporate Secretary
- H. Stewart Parker, Chair of the Board
- Courtney Beers, Ph.D.,
- Robert Carey,
- Kenneth Hillan, M.B. Ch.B.,
- Margaret (Peg) A. Horn, J.D.,
- John Markels, Ph.D.,
- James R. Meyers,
- Karen Smith, M.D., Ph.D., M.B.A., LLM,
Last updated: 2024-12-31
Passage Bio, Inc.
PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06
Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.
Symbol: PASG
Recent Price: $0.67
Industry: Biotechnology
CEO: Dr. William Chou M.D.
Sector: Healthcare
Employees: 58
Address: One Commerce Square, Philadelphia, PA 19103
Phone: 267 866 0311
Leadership
- William Chou, MD, President and Chief Executive Officer
- Kathleen Borthwick, Chief Financial Officer
- Sue Browne, PhD, Chief Scientific Officer
- Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
- Eden Fucci, SVP Technical Operations
- Stuart Henderson, Chief Business Officer
- Karl Whitney, PhD, SVP Global Regulatory Affairs
- James M. Wilson, MD, PhD, Scientific Advisor
- Maxine Gowen, PhD, Chairwoman
- Athena Countouriotis, MD,
- Derrell D. Porter, MD,
- Dolan Sondhi, PhD,
- Sandip Kapadia,
- Tom Kassberg,
- Saqib Islam,
- Samiah Al-Zaidy, MD, Vice President, Clinical Development
- Andrea Campanile, Vice President, Clinical Operations
Last updated: 2024-12-31
Agenus Inc.
Retrocyte Display
Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.
Symbol: AGEN
Recent Price: $2.69
Industry: Biotechnology
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Employees: 389
Address: 3 Forbes Road, Lexington, MA 02421-7305
Phone: 781 674 4400
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
BeiGene, Ltd.
BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy
Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.
About | About | Vision/Values | About | About | Culture | DEI | Culture | Leadership | About | Contact | Careers | Careers | Careers | Careers | About | About | About | About | About | Jobs | About | About | About
Symbol: BGNE
Recent Price: $183.81
Industry: Biotechnology
CEO: Mr. John V. Oyler
Sector: Healthcare
Employees: 10000
Address: 55 Cambridge Parkway, Cambridge, MA 02142
Phone: 781-801-1800
Leadership
- John V. Oyler, Co-Founder, Chairman and CEO
- Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
- Olivier Brandicourt, M.D., Director
- Margaret Dugan, M.D., Director
- Donald W. Glazer, Director
- Michael Goller, Director
- Anthony Hooper, Director
- Ranjeev Krishana, Director
- Michael Nuoqing Yi, Director
- Alessandro Riva, M.D., Director
- Corsee Sanders, Ph.D., Director
- Shalini Sharp, Director
- Steven Young, Ph.D., Acting Head of Medicinal Chemistry
- Ron Levy, M.D., Scientific Advisory Board
- Neal Rosen, M.D., Ph.D., Scientific Advisory Board
- Charles Sawyers, M.D., Scientific Advisory Board
- David Schenkein, M.D., Scientific Advisory Board
- Melika Davis, SVP & Global Head, Clinical Operations
- Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
- Tony Guo, Ph.D., SVP, Global Statistics & Data Science
- Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
- Graham Hardiman, Global Head of HR
- Shreya Devendra Jani, SVP, Corporate Affairs
- Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
- Yang Ji, Chief Compliance Officer
- Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
- Chan Lee, General Counsel
- Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
- Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
- Kyoung Lim, VP of Supply Chain
- Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
- Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
- Richard O’Keeffe, Head of Global Quality
- Jurij Petrin, M.D., Head of New Market Development
- Yan Qi, Ph.D., SVP, Head of Public Affairs
- Hongyu Qian, SVP, Medical Affairs
- Jason Radford, SVP, Strategy & Corporate Development
- Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
- Adam Roach, VP and Head of Asia Pacific
- Aaron Rosenberg, Chief Financial Officer
- Michael Schoen, Strategic Advisor and Special Assistant to the CEO
- Matt Shaulis, General Manager of North America
- Lai Wang, Ph.D., Global Head of R&D
- Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
- Beth Wensley, SVP, Head of Portfolio and Program Management
- Kimberly Wolf, SVP, Global Commercial Strategy & Operations
- Xiaobin Wu, Ph.D., President, Chief Operating Officer
- Eva Yin, Chief Commercial Officer, Greater China
Last updated: 2024-12-31
bluebird bio, Inc.
betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel
bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
About | Leadership | DEI | About | About | About | Contact | Careers | About | About | About | About
Symbol: BLUE
Recent Price: $7.86
Industry: Biotechnology
CEO: Mr. Andrew Obenshain
Sector: Healthcare
Employees: 375
Address: 60 Binney Street, Cambridge, MA 02142
Phone: 339 499 9300
Leadership
- Sarah Alspach, Senior Vice President, External Affairs
- Rich Colvin, MD, PhD, Chief Medical Officer
- Kasra Kasraian, Senior Vice President, Technical Development and Operations
- Tom Klima, Chief Commercial & Operating Officer
- Andrew Obenshain, Chief Executive Officer
- Scott Shoemaker, Senior Vice President, Quality
- James Sterling, Chief Financial Officer
- Joe Vittiglio, Chief Business and Legal Officer
- Andrea Walton, Chief People Officer
- Leslie Wilder, Vice President, Head of Regulatory Science
- Mark Vachon, Chairman; Formerly of GE
- John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
- Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
- Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
- Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
- Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
- Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
- Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Generation Bio Co.
genetic medicines
Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.
Symbol: GBIO
Recent Price: $1.06
Industry: Biotechnology
CEO: Dr. Cameron Geoffrey McDonough M.D.
Sector: Healthcare
Employees: 174
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 655 7500
Last updated: 2024-12-31
Korro Bio, Inc.
genetic medicines based on editing RNA
Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing to treat rare and widespread diseases. The company is based in Cambridge, Massachusetts and aims to provide clinical benefits through their innovative approach.
Symbol: KRRO
Recent Price: $38.11
Industry: Biotechnology
CEO: Mr. Ram Aiyar MBA, Ph.D.
Sector: Healthcare
Employees: 92
Address: One Kendall Square, Cambridge, MA 02139-1562
Phone: 781-315-4600
Last updated: 2024-12-31
Neurogene Inc.
NGN-401, NGN-101
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.
About | Contact | Contact | Careers | Jobs | Jobs | Jobs | Benefits | Jobs | Jobs | Jobs | Jobs | Careers | About | About | About
Symbol: NGNE
Recent Price: $22.28
Industry: Biotechnology
CEO: Dr. Rachel L. McMinn Ph.D.
Sector: Healthcare
Employees: 91
Address: 535 W 24th Street, New York, NY 10011
Phone: (877) 237-5020
Last updated: 2024-12-31
Prime Medicine, Inc.
Prime Editors
Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies using gene editing technology. Headquartered in Cambridge, Massachusetts, the company was founded in 2019.
About | About | About | Careers | Careers | About | About | About | About | About | Contact | Careers | Careers | About | About
Symbol: PRME
Recent Price: $2.78
Industry: Biotechnology
CEO: Dr. Keith Michael Gottesdiener M.D., Ph.D.
Sector: Healthcare
Employees: 234
Address: 21 Erie Street, Cambridge, MA 02139
Phone: 617-564-0013
Last updated: 2024-12-31
Solid Biosciences Inc.
SGT-001
Solid Biosciences Inc. focuses on developing therapies for Duchenne muscular dystrophy, with lead product candidates like SGT-001 and SGT-003, and platform technologies like dual gene expression. The company is headquartered in Cambridge, Massachusetts, and collaborates with Ultragenyx Pharmaceutical Inc.
Vision/Values | Vision/Values | Vision/Values | About | Management | Directors | About | About | About | Culture | Benefits | About | Culture | Vision/Values | Contact | Contact | About | About
Symbol: SLDB
Recent Price: $4.07
Industry: Biotechnology
CEO: Mr. Alexander G. Cumbo
Sector: Healthcare
Employees: 88
Address: 141 Portland Street, Cambridge, MA 02139
Phone: 617 337 4680
Leadership
- Ian F. Smith, Chairman of the Board
- Bo Cumbo, President and CEO
- Martin Freed, M.D., F.A.C.P., Board Member
- Ilan Ganot, Co-Founder and Strategic Advisor to the CEO
- Clare Kahn, Ph.D., Board Member
- Georgia Keresty, Ph.D., M.PH., Board Member
- Sukumar Nagendran, M.D., President, Head of Research & Development, Taysha Gene Therapies
- Adam Stone, Chief Investment Officer of Perceptive Advisors
- Lynne Sullivan, Chief Financial Officer at Unity Biotechnology
Last updated: 2024-12-31
Synlogic, Inc.
Synthetic Biotic Medicines
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.
Symbol: SYBX
Recent Price: $1.40
Industry: Biotechnology
CEO: Mr. Antoine Awad
Sector: Healthcare
Employees: 6
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 401 9975
Last updated: 2024-12-31
Syros Pharmaceuticals, Inc.
Tamibarotene
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.
About | Leadership | Directors | About | Contact | Careers | Vision/Values | DEI | Careers | About | About
Symbol: SYRS
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Conley Chee
Sector: Healthcare
Employees: 68
Address: 35 CambridgePark Drive, Cambridge, MA 02140
Phone: 617 744 1340
Leadership
- Conley Chee, President and Chief Executive Officer
- Jason Haas, Chief Financial Officer
- Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
- Lisa Roberts, VP Human Resources
- David A. Roth, M.D., Chief Medical Officer
- Kristin Stephens, Chief Development Officer
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
MeiraGTx Holdings plc
Gene Therapy Treatments
Meira GTx Holdings plc is a clinical stage gene therapy company developing treatments for serious diseases, including ocular diseases, xerostomia, and neurodegenerative conditions. They are in various stages of clinical development for several gene therapy programs and have a research collaboration with Janssen Pharmaceuticals.
About | Leadership | About | Contact | About | About | About | News | About | About | About | Directors
Symbol: MGTX
Recent Price: $5.89
Industry: Biotechnology
CEO: Dr. Alexandria Forbes Ph.D.
Sector: Healthcare
Employees: 387
Address: 430 East 29th Street, New York, NY 10016
Phone: 646 860 7985
Leadership
- Alexandria Forbes, Ph.D., Board Member, President and Chief Executive Officer
- Richard Giroux, Chief Operating Officer and Chief Financial Officer
- Stuart Naylor, Ph.D., Chief Development Officer
- Robert K. Zeldin, M.D., Chief Medical Officer
- Robert Wollin, JD, General Counsel and Secretary
- Alastair Leighton, Ph.D, SVP, Manufacturing and Supply Chain
- Christine Sheehy, SVP, Global Integration
- Tim Randall, SVP, Risk and Internal Controls
- Michel Michaelides, M.D., Head of Clinical Ophthalmology
- Tassos Georgiadis, Ph.D., Vice President, Preclinical Development
- Keith R. Harris, Ph.D., Chairman of the Board
- Ellen Hukkelhoven, Ph.D., Board Member
- Lord Mendoza, Independent Board Member
- Nicole Seligman, Independent Board Member
- Thomas E. Shenk, Ph.D., Independent Board Member
- Debra Yu, M.D., Independent Board Member
Last updated: 2024-12-31